ArticleObesity science & practice2025
Naltrexone/Bupropion, Liraglutide, or Semaglutide as Adjuvant Therapy After Metabolic and Bariatric Surgery: An Observational Study.
Article in Obesity science & practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Naltrexone/Bupropion, Liraglutide, or Semaglutide as Adjuvant Therapy After Metabolic and Bariatric Surgery: An Observational Study.Obesity science & practice · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Obesity is a chronic and relapsing disease and metabolic and bariatric surgery (MBS) provides the greatest weight loss efficacy to improve obesity related complications. However, weight recurrence and suboptimal weight loss occur in some patients leading to a recurrence of disease. Obesity management medications (OMM) to prevent and manage excess weight after MBS are now being recommended. The aim of the study was to determine the efficacy of OMM prescribed for recurrent weight gain (RWG) or suboptimal weight loss (SWL) after primary and conversional bariatric metabolic surgery. Methods: Patients were prescribed either a fixed-dose extended-release combination of naltrexone and bupropion (NB-ER; 8 mg/90 mg), liraglutide (3.0 mg), or semaglutide (1.0 mg) for RWG and/or SWL following adjustable gastric banding (LAGB), sleeve gastrectomy (LSG), one anastomosis gastric bypass (OAGB), or conversional procedures. Data were reported as categorical values using either parametric or nonparametric statistics. Results: For the 121 patients analyzed, baseline characteristics were similar at initiation of OMM. Among these patients, 59.7% underwent LSG, 11.8% underwent OAGB, 6.7% underwent LAGB, and 21.8% underwent conversional procedures. Patients regained a median of 9.7 kg (IQR; 5-18.1) or 27.9% (IQR; 15.7-57.8) of total body weight previously lost following MBS. In total, 34 patients (28.1%) were prescribed NB-ER, 23 patients (19.1%) were prescribed liraglutide, and 64 patients (52.8%) were prescribed semaglutide post MBS. Overall, patients prescribed OMM treatment lost 8.8% (IQR; 5.7-14.1; median follow-up, 9 months [IQR; 5-12]) total body weight. Adverse effects were minor and reflected clinical trial nonsurgical cohorts. Conclusion: Adjuvant OMM conferred additional significant weight loss in patients with RWG or SWL in both primary and conversional surgical procedures and all three OMM studied should be considered as part of MBS aftercare.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.